Friday, June 13, 2025 The Zacks Research Daily presents the best research output of our analyst team. Today’s Research Daily features new research reports on 16 major stocks, including Eli Lilly ...

Eli Lilly (NYSE: LLY) has been a great growth pick for investors over the past few years. The pharma company, thanks to its weight loss drug portfolio, has seen revenue climb in the double digits ...

Eli Lilly (NYSE: LLY) stock hasn't been doing too well this year, but that could change later this month. If Eli Lilly presents strong data, the stock could be set to rally and potentially be on a ...

Eli Lilly (LLY) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.

We came across a bullish thesis on Eli Lilly and Company (LLY) on Business Model Mastery’s Substack. In this article, we will summarize the bulls’ thesis on LLY.

Eli Lilly & Co. increased sales of weight-loss and diabetes drug Mounjaro 60% in India in May from April in its second full month of being on offer in the South Asian country, which has the world ...

On June 5, TD Cowen analysts trimmed the price target for Eli Lilly and Company (NYSE:LLY) from $1,050 to $960, while reiterating a Buy rating on the stock. This target price adjustment aligns ...

Eli Lilly and Company thrives on its groundbreaking weight-loss drug tirzepatide. Learn why we could see a $50B market and the risks. Click for my LLY stock update.

Deals: Sanofi picked up Blueprint Medicines in a deal worth up to $9.5 billion.. Bristol Myers Squibb will pay $1.5 billion upfront to partner with BioNTech on an experimental cancer drug.. Astellas ...

Erste Group has downgraded Eli Lilly from a buy to a hold rating due to concerns about its earnings forecast. Despite 36.38% revenue growth and a strong drug pipeline, the company's revised 2025 ...